Pfizer claims employee stole COVID-19 vaccine documents
25-11-2021
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
06-09-2021
Pfizer drops Xeljanz patent suits
20-04-2021
Flowersandtraveling / Shutterstock.com
Pfizer is the latest pharmaceutical company to sign a licensing agreement with the Medicines Patent Pool (MPP) to help increase access to its COVID-19 oral antiviral treatment candidate PAXLOVID (PF-07321332) for low and middle-income countries.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pfizer, COVID-19, MPP, Charles Gore, Albert Bourla, big pharma
